SomaLogic, Inc. (SLGC)

Overview

SomaLogic, Inc. stands as a distinguished entity focused on the discovery of protein biomarkers and the provision of clinical diagnostics within the United States. Since its inception in 1999 and from its headquarters in Boulder, Colorado, the company has dedicated itself to the advancement of slow off-rate modified aptamers (SOMAmers), which are tailored nucleic acid-based reagents that bind specifically to proteins. This innovation underpins their proprietary SomaScan services, designed to perform multiplex protein detection and quantification within complex biological samples. SomaLogic's contribution to the domain of proteomics and diagnostics is marked by their collaboration agreement with Illumina Cambridge, Ltd., targeting the development of next-generation sequencing (NGS)-based proteomic distributable kits, which highlights the company’s role in bridging cutting-edge genomic and proteomic technologies.

Products and Services

• SOMAmers (Slow Off-Rate Modified Aptamers)

These are customized nucleic acid-based protein-binding reagents that exhibit specificity for their corresponding proteins. The unique design of SOMAmers enables a high fidelity in protein capture and detection, facilitating the analysis of a myriad of proteins across various biological samples. This technology provides a foundational component for the company’s broader research and diagnostic applications, enabling the identification of protein biomarker signatures pivotal in drug discovery, diagnostic developments, and disease research.

• SomaScan Services

Offering a comprehensive solution for multiplex protein detection and quantification, SomaScan services leverage the company’s proprietary technology to analyze complex biological samples for protein biomarkers. This platform not only supports academic and governmental research but also enables pharmaceutical and biotechnology companies to advance in their drug discovery and development efforts. By offering insights into protein levels and interactions, these services aid in identifying potential therapeutic targets and understanding disease mechanisms.

• SomaSignal

Recognized as a laboratory-developed test, SomaSignal represents SomaLogic’s foray into diagnostic applications. This service leverages the company’s protein analysis platforms to provide diagnostic insights, potentially allowing for the early detection of various conditions, including cardiovascular and metabolic diseases, nonalcoholic steatohepatitis, and other wellness indicators. By employing the biomarker discovery capabilities of the SomaScan platform, SomaSignal offers a promising tool for the personalized diagnosis and monitoring of numerous health conditions.